CAR-T细胞免疫疗法在实体瘤中的研究进展  

Research progress of CAR-T cell immunotherapy in solid tumors

作　　者：张淑群[1] 马兴聪 孙诗雨 冯聪 贾艺玮 ZHANG Shuqun;MA Xingcong;SUN Shiyu;FENG Cong;JIA Yiwei(Department of Oncology,The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710004,China)

机构地区：[1]西安交通大学第二附属医院肿瘤病院,西安710004

出　　处：《西南医科大学学报》2024年第2期98-103,共6页Journal of Southwest Medical University

基　　金：国家自然科学基金青年项目(82003047);吴阶平医学基金会(320.6750.2022-19-79);陕西省中西医结合肿瘤防治重点实验室建设项目(2022-ZXY-SYS-002)。

摘　　要：嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)成功治疗复发难治性白血病的历史已超过十年,如今,已有多款CAR-T细胞疗法获批用于治疗白血病和淋巴瘤等血液系统癌症,标志着免疫细胞治疗时代的到来。大量研究结果提示,CAR-T细胞疗法在实体瘤治疗领域同样充满潜力,但相关临床研究数据却不令人满意。CAR-T细胞疗法在实体瘤中面临靶抗原特异性不足、肿瘤物理屏障、异常代谢及免疫抑制性肿瘤微环境等多重不利因素,需要继续深入相关机制的研究,借助基因工程技术对CAR-T细胞进行改造,进一步提升其对实体瘤的疗效。本文就近年来CAR-T细胞疗法在实体瘤中的研究进展做一述评,探讨未来CAR-T细胞治疗的挑战和发展方向。Chimeric antigen receptor T cell(CAR-T)therapy has achieved remarkable successes in treating refractory leuke-mia and other hematologic malignancies in the past ten years.At present,the FDA has approved six CAR-T cell products for hemato-logic malignancies including leukemia,lymphoma,etc.,highlighting the arrival of the era of immunotherapy and cell therapy for cancer.A large number of studies have indicated the potential of CAR-T cells in solid tumors.However,data from clinical trials was far from satisfactory yet.Obstacles interfering with the therapeutic effects of CAR-T cell therapy in solid tumors have been identified,including lack of reliable tumor-associated antigens,physical barriers within tumors,metabolic stress,immunosuppressive tumor environments,etc.Efforts should be made to further investigate the underlying mechanisms,and gene engineering technologies holds great potential for generation of more effective CAR-T strategies.This review aimed to provide a landscape view of recent progress for CAR-T cell therapy in solid tumors and discussed the challenges and future directions of CAR-T cell therapy.

关 键 词：嵌合抗原受体T细胞 免疫治疗 实体瘤 

分 类 号：R730.5[医药卫生—肿瘤]